Muscle & Nerve

• 

  Publication Venue For

  • The CINRG Becker Natural History Study: Baseline characteristics..  62:369-376. 2020
  • Jože Trontelj; june 1, 1939 to december 9, 2013 2014
  • Lyme disease serology in amyotrophic lateral sclerosis..  40:626-628. 2009
  • Jitter recordings with concentric needle electrodes..  40:331-339. 2009
  • DIAGNOSTIC CRITERIA FOR LATE-ONSET (CHILDHOOD AND ADULT) POMPE DISEASE.  40:149-160. 2009
  • Diagnostic criteria for late-onset (childhood and adult) Pompe disease..  40:149-160. 2009
  • Median nerve ultrasonography in carpal tunnel syndrome: findings from two laboratories..  40:94-97. 2009
  • Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory..  40:32-36. 2009
  • Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite..  38:1553-1562. 2008
  • Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis..  38:1429-1433. 2008
  • Reply.  38:1214. 2008
  • Disease-specific measure of quality of life for myasthenia gravis..  38:947-956. 2008
  • Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis..  38:957-963. 2008
  • Myotilin overexpression enhances myopathology in the LGMD1A mouse model..  37:663-667. 2008
  • The more the merrier?.  37:555-559. 2008
  • Mechanisms underlying reversal of motor unit activation order in electrically evoked contractions after spinal cord injury..  37:210-218. 2008
  • Morphology and ultrastructure of differentiating three-dimensional mammalian skeletal muscle in a collagen gel..  36:71-80. 2007
  • Certification in neuromuscular medicine: a new neurologic subspecialty..  35:409-410. 2007
  • Variable presentation of nemaline myopathy: novel mutation of alpha actin gene..  35:254-258. 2007
  • Sural neuropathy: etiologies and predisposing factors..  34:482-484. 2006
  • A model of muscle atrophy using cast immobilization in mice..  32:672-674. 2005
  • Noninvasive monitoring of muscle damage during reloading following limb disuse..  32:605-612. 2005
  • Needle EMG in certain uncommon clinical contexts..  31:398-399. 2005
  • MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy..  29:364-368. 2004
  • Preferential motor reinnervation in the mouse: comparison of femoral nerve repair using a fibrin sealant or suture..  28:227-231. 2003
  • The utility of magnetic resonance imaging in evaluating peripheral nerve disorders..  25:314-331. 2002
  • Titin and nebulin content in human skeletal muscle following eccentric resistance exercise..  25:289-292. 2002
  • Steroid treatment for myasthenia gravis: steroids have an important role..  25:117-121. 2002
  • Normal skeletal muscle Na(+)-K(+) pump concentration in patients with chronic heart failure..  24:69-76. 2001
  • Some observations on fibrillations and positive sharp waves..  23:888-894. 2000
  • Electrophysiological evidence for afferent nerve fibers in human ventral roots..  23:410-415. 2000
  • Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy..  22:1693-1697. 1999
  • Myasthenia gravis in the tenth decade..  22:1297-1298. 1999
  • Guidelines for ethical behavior relating to clinical practice issues in electrodiagnostic medicine.  22. 1999
  • Thoraconeuralgia gravidarum..  22:779-780. 1999
  • Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy..  22:532-537. 1999
  • A skin blister method to study epidermal nerves in peripheral nerve disease.  22:360-371. 1999
  • Fulminant demyelinating neuropathy mimicking cerebral death..  20:1595-1597. 1997
  • AAEM minimonograph #25: single-fiber electromyography..  19:1069-1083. 1996
  • A syndrome of concurrent central and peripheral nervous system involvement due to Epstein-Barr virus infection..  19:1037-1039. 1996
  • Tenascin-C expression in dystrophin-related muscular dystrophy..  19:147-154. 1996
  • Clinical correlates in the deep tendon reflexes of the electrophysiology in the Lambert-Eaton myasthenic syndrome and myasthenia gravis..  18:920-921. 1995
  • Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome..  17:995-1001. 1994
  • Single fiber EMG and repetitive stimulation of the same muscle in myasthenia gravis..  17:171-175. 1994
  • Bell's palsy: an eponym that often leads to confusion..  17:119. 1994
  • Letters to the editor.  17:112-120. 1994
  • Single fiber electromyography in myasthenia gravis during pregnancy..  16:458-460. 1993
  • MUAP analysis using Bayes classifier..  15:967-968. 1992
  • The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome..  15:256-258. 1992
  • Letters to the editor.  15:255-258. 1992
  • Letters to the editor.  15:964-972. 1992
  • Immobilization-induced changes in motor unit force and fatigability in the cat..  14:563-573. 1991
  • Recording characteristics of monopolar EMG electrodes..  14:108-112. 1991
  • On the shape of the normal turns--amplitude cloud..  14:8-13. 1991
  • Measurement of the amplitude of the EMG envelope..  13:933-938. 1990
  • Recording and physical characteristics of disposable concentric needle EMG electrodes..  13:909-914. 1990
  • Quantitative EMG in inflammatory myopathy..  13:247-253. 1990
  • COMPARISON OF REFERRING DIAGNOSES AND ELECTRODIAGNOSTIC FINDINGS IN AN ACADEMIC EMG LABORATORY.  12:757-757. 1989
  • DECOMPOSITION OF CONCENTRIC NEEDLE EMG MOTOR UNIT ACTION-POTENTIALS.  12:752-753. 1989
  • QUANTITATIVE EMG MYOTONIC-DYSTROPHY.  12:761-761. 1989
  • RECORDING CHARACTERISTICS OF CONCENTRIC VS MONOPOLAR NEEDLE EMG ELECTRODES.  12:756-756. 1989
  • RECORDING CHARACTERISTICS OF DISPOSABLE VERSUS REUSABLE CONCENTRIC EMG NEEDLE ELECTRODES.  12:753-753. 1989
  • Ephaptic transmission in hemifacial spasm: a single-fiber EMG study..  12:690-694. 1989
  • Principal component analysis of the features of concentric needle EMG motor unit action potentials..  12:288-293. 1989
  • Simulation of myopathic motor unit action potentials..  12:197-202. 1989
  • Evaluation of an automatic method of measuring features of motor unit action potentials..  12:141-148. 1989
  • The effect of cholinesterase inhibitors of SFEMG in myasthenia gravis..  12:154-155. 1989
  • Myasthenic U-shaped decrement in multifocal cervical radiculopathy..  12:64-66. 1989
  • DIAGNOSTIC SENSITIVITY OF QUANTITATIVE MOTOR UNIT ACTION-POTENTIAL ANALYSIS.  11:966-966. 1988
  • EMG STUDIES IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS RECEIVING THYROTROPIN-RELEASING-HORMONE.  11:976-976. 1988
  • QUANTITATIVE EMG IN THE POSTPOLIO MUSCULAR-ATROPHY SYNDROME.  11:959-959. 1988
  • Simulation of concentric needle EMG motor unit action potentials..  11:151-159. 1988
  • SFEMG IN MYASTHENIA-GRAVIS - REPLY.  10:837-837. 1987
  • A COMPUTER-BASED EMG REPORT-GENERATION AND DATABASE SYSTEM.  10:669-669. 1987
  • COMPUTER-AIDED EMG FINDINGS IN INFLAMMATORY MYOPATHY.  10:662-662. 1987
  • EPHAPTIC TRANSMISSION IN HEMIFACIAL SPASM - A SINGLE FIBER EMG STUDY.  10:663-663. 1987
  • SERIAL QUANTITATIVE EMG STUDIES IN MOTOR-NEURON DISEASE.  10:661-661. 1987
  • SINGLE FIBER ELECTROMYOGRAPHY IN MYASTHENIA-GRAVIS DURING PREGNANCY.  10:667-667. 1987
  • Single fiber electromyography in chronic progressive external ophthalmoplegia..  10:299-302. 1987
  • Double-step repetitive stimulation in myasthenia gravis..  10:233-237. 1987
  • Letters to the editor.  10:837-840. 1987
  • AN AUTOMATED-METHOD OF MEASURING MOTOR UNIT ACTION-POTENTIAL FEATURES - FINDINGS IN NERVE AND MUSCLE DISEASES.  9:667-667. 1986
  • THE EFFECT OF CHOLINESTERASE-INHIBITORS ON SINGLE-FIBER ELECTROMYOGRAPHY IN MYASTHENIA-GRAVIS.  9:660-660. 1986
  • AUTOMATIC-ANALYSIS OF THE ELECTROMYOGRAPHIC INTERFERENCE PATTERN (ANALYSIS OF NUMBER OF SMALL TURNS, AMPLITUDE AND RECRUITMENT - ANSTAR).  9:571-571. 1986
  • EFFECT OF TEMPERATURE ON NEUROMUSCULAR-TRANSMISSION.  9:573-573. 1986
  • NEUROPHYSIOLOGIC MONITORING IN MYASTHENIA-GRAVIS.  9:562-562. 1986
  • THE EFFECT OF FIRING RATE ON NEUROMUSCULAR JITTER.  9:566-566. 1986
  • Automatic analysis of the electromyographic interference pattern. Part I: Development of quantitative features..  9:431-439. 1986
  • Simulation and analysis of the electromyographic interference pattern in normal muscle. Part I: Turns and amplitude measurements..  9:423-430. 1986
  • Promiscuous expression of myosin in myotonic dystrophy..  9:355-363. 1986
  • AAEE minimonograph #25: Single-fiber electromyography in myasthenia gravis..  9:809-819. 1986
  • Automatic analysis of the electromyographic interference pattern. Part II: Findings in control subjects and in some neuromuscular diseases..  9:491-500. 1986
  • Simulation and analysis of the electromyographic interference pattern in normal muscle. Part II: Activity, upper centile amplitude, and number of small segments..  9:486-490. 1986
  • The ischemic exercise test in normal adults and in patients with weakness and cramps..  9:216-221. 1986
  • WHAT WE HAVE LEARNED ABOUT THE ABNORMAL MOTOR UNIT.  9:83-83. 1986
  • AUTOMATIC-MEASUREMENT OF MOTOR UNIT ACTION-POTENTIAL DURATION.  8:626-626. 1985
  • SINGLE FIBER ELECTROMYOGRAPHY IN CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA.  8:624-624. 1985
  • THE DOUBLE-STEP TECHNIQUE OF REPETITIVE NERVE-STIMULATION.  8:624-624. 1985
  • USE OF SINGLE FIBER ELECTROMYOGRAPHY TO PREDICT THE COURSE OF OCULAR MYASTHENIA.  8:624-624. 1985
  • NUMBER OF TURNS IN THE EMG INTERFERENCE PATTERN MEASURED AT DIFFERENT FORCE LEVELS IN BICEPS.  7:561-561. 1984
  • SIMULATION OF CONCENTRIC NEEDLE EMG MOTOR UNIT ACTION-POTENTIALS.  7:562-562. 1984
  • Recombinant DNA strategies in genetic neurological diseases..  6:339-355. 1983
  • Myotonic muscular dystrophy: morphology, histochemistry, and growth characteristics of cultured skin fibroblasts..  5:125-130. 1982
  • THE MOTOR UNIT IN AMYOTROPHIC LATERAL SCLEROSIS - A MACRO EMG STUDY.  5:556-556. 1982
  • "Hunkering"; and peroneal palsy..  4:445. 1981
  • "Hunkering"; and peroneal palsy..  4:445. 1981
  • Gonyalgia paresthetica..  4:80-81. 1981
  • Gonyalgia paresthetica..  4:80-81. 1981
  • Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states..  3:112-119. 1980
  • Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission..  3:105-111. 1980
  • Red blood cell and fibroblast membranes in Duchenne and myotonic muscular dystrophy..  3:36-54. 1980
  • Effects of D-penicillamine on neuromuscular transmission in rats..  2:180-185. 1979
  • High-dose daily prednisone therapy in the treatment of myasthenia gravis.  1:342-343. 1978
  • Median neuropathy affecting the first dorsal interosseous muscle..  1:501. 1978
  • Neonatal experimental autoimmune myasthenia gravis..  1:146-150. 1978
  • CD8 T CELL IMMUNE SIGNATURES IN AUTOIMMUNE MYASTHENIA GRAVIS 2022
  • CONSISTENT EFFICACY OF RAVULIZUMAB ACROSS SEX AND AGE SUBGROUPS OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: A POST HOC ANALYSIS OF THE CHAMPION MG STUDY 2022
  • COVID-19 VACCINE SAFETY IN PATIENTS WITH MYASTHENIA GRAVIS 2022
  • SERUM AUTOANTIBODY LOWERING BY THE ANTI-FCRN MONOCLONAL ANTIBODY, NIPOCALIMAB, CORRELATES WITH CLINICAL IMPROVEMENT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS 2022
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS 2022
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: THYMECTOMY IN MUSK MYASTHENIA 2022
  • ANALYSIS OF THE DUKE MYASTHENIA GRAVIS (MG) CLINIC REGISTRY: THYMECTOMY 2021
  • EFFICACY AND SAFETY OF CIPAGLUCOSIDASE ALFA/MIGLUSTAT VERSUS ALGLUCOSIDASE ALFA/PLACEBO IN LATE-ONSET POMPE DISEASE: A PHASE 3 TRIAL (PROPEL) 2021
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: FACTORS PREDICTING GENERALIZATION OF OCULAR MG 2021
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS 2021
  • IMMUNE CHECKPOINT INHIBITOR MEDIATED INFLAMMATORY POLYNEUROPATHY 2020
  • KNOWLEDGE AND PERCEPTIONS OF THE COVID-19 PANDEMIC AMONG PATIENTS WITH MYASTHENIA GRAVIS 2020
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS 2020
  • THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS 2020
  • NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE 2019
  • NERVE ROOT HYPERTROPHY CAUSING SPINAL STENOSIS IN HEREDITARY AND AUTOIMMUNE DEMYELINATING NEUROPATHY 2019
  • OCULAR NON-THYMOMATOUS SEROPOSITIVE MYASTHENIA GRAVIS WITH MINIMAL DISEASE MANIFESTATIONS ASSOCIATED WITH ACQUIRED RIPPLING MUSCLE DISEASE 2019
  • FIRST-IN-HUMAN STUDY OF AT-GAA (ATB200/AT2221) IN PATIENTS WITH POMPE DISEASE: PRELIMINARY RESULTS FROM THE ATB200-02 TRIAL 2018
  • MUSK MYASTHENIA GRAVIS IS ASSOCIATED WITH AN IMBALANCE IN TFH17 CELL SUBSETS 2018
  • VALIDATION OF THE TRIPLE TIMED UP-AND-GO TEST FOR CLINICAL ASSESSMENT IN LAMBERT-EATON MYASTHENIA PATIENTS 2018
  • VALIDATION OF THE TRIPLE TIMED UP-AND-GO TEST FOR CLINICAL ASSESSMENT IN LAMBERT-EATON MYASTHENIA PATIENTS 2018
  • OXYNEUROGRAPHY STUDY OF TOURNIQUET-INDUCED CHANGES IN NERVE TISSUE OXYGENATION 2016
  • PK/PD MODELING AND SIMULATION OF 3,4-DIAMINOPYRIDINE BASE IN PATIENTS WITH LAMBERT-EATON MYASTHENIA SYNDROME 2016
  • B10 DEFICIENCY IN MYASTHENIA GRAVIS IS NOT ASSOCIATED WITH DEFECTIVE T CELL SUPPRESSION 2016
  • EFFECT OF THERAPEUTIC PLASMA EXCHANGE ON IMMUNOGLOBULINS 2015
  • RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERTEATON MYASTHENIC SYNDROME (LEMS) 2015
  • T CELL REACTIVITY IN INCLUSION BODY MYOSITIS (IBM) 2015
  • RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERT-EATON MYASTHENIC SYNDROME 2015
  • COMPARISON OF B10 CELLS IN IMMUNOSLTPPRESSED AND IMMUNOSUPPRESSION NAIVE ACHR plus MG 2014
  • PARALLEL CLINICAL AND JITTER CHANGES DURING RAPID, ECULIZUMAB-INDUCED MYASTHENIC REMISSION 2014
  • THE EFFECTS OF TIRASEMTIV, A FAST SKELETAL MUSCLE TROPONIN ACTIVATOR, ON MEASURES OF RESPIRATORY FUNCTION IN NEUROMUSCULAR DISEASES 2014
  • PROLONGED B CELL DEPLETION IN MUSK MYASTHENIA GRAVIS FOLLOWING RITUXIMAB TREATMENT 2013
  • DO ULTRASOUND CHARACTERISTICS CORRELATE WITH ELECTRODIAGNOSTIC FINDINGS IN INFLAMMATORY NEUROPATHIES? 2012
  • DOES CHANGE IN ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) LEVEL PREDICT OR CORRELATE WITH CLINICAL CHANGE IN MG? 2012
  • DOES THE ACETYLCHOLINE RECEPTOR ANTIBODY LEVEL PREDICT OR CORRELATE WITH THE OUTCOME IN MG? 2012
  • DOES THE PRESENCE OR LEVEL OF ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) PREDICT GENERALIZATION IN OCULAR MYASTHENIA (OM)? 2012
  • MEDIAN NERVE ULTRASOUND AS A SCREENING TOOL IN CARPAL TUNNEL SYNDROME: CORRELATION OF CROSS-SECTIONAL AREA MEASURES WITH ELECTRODIAGNOSTIC ABNORMALITY 2012
  • SONOGRAPHIC AND ELECTRODIAGNOSTIC CHARACTERISTICS OF DIABETIC CARPAL TUNNEL SYNDROME 2012
  • SONOGRAPHICALLY-MEASURED NERVE SIZE AND INTRA-NERVE SIZE VARIABILITY IN INFLAMMATORY POLYNEUEROPATHY 2012
  • DO ANTIBODIES PREDICT THE PRESENCE OR ABSENCE OF THYMOMA IN MYASTHENIA GRAVIS? 2011
  • INCREASED OCCURRENCE OF LATE ONSET MYASTHENIA GRAVIS 2011
  • MEDIAN NERVE ULTRASOUND AS A SCREENING TOOL IN CARPAL TUNNEL SYNDROME 2011
  • PLASMA EXCHANGE COMPLICATIONS ARE RELATED TO THE VENOUS ACCESS ROUTE 2011
  • RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER, PHASE II STUDY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG) 2011
  • THE EFFECT OF TRANSUDCER FREQUENCY ON ULTRASONOGRAPHIC MUSCLE LUMINOSITY MEASURES 2011
  • LABORATORY EXPERIENCE OF USING DRIED BLOOD SPOT ASSAY TO DIAGNOSE POMPE DISEASE 2009
  • Lambert-Eaton myasthenic syndrome: Findings in 97 patients 2006
  • Multifocal motor neuropathy with upper motor neuron signs 2006
  • Muscle-specific kinase antibody myasthenia gravis: Response to treatment in 25 patients 2006
  • Metronidazole: A newly recognized cause of autonomic neuropathy 2004
  • Peripheral nerve ultrasound as an adjunct to electrodiagnostic testing 2004